Literature DB >> 17659955

Treatment of exudative age-related macular degeneration: many factors to consider.

Timothy W Olsen1.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17659955      PMCID： PMC2040182          DOI： 10.1016/j.ajo.2007.05.005

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN： 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  17 in total

1.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; Andrew A Moshfeghi; Carmen A Puliafito
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2005 Jul-Aug

2.  The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration.

Authors:  Robert Steinbrook
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

3.  Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

Authors:  M S Gordon; K Margolin; M Talpaz; G W Sledge; E Holmgren; R Benjamin; S Stalter; S Shak; D Adelman
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

4.  Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Authors:  Ryan M Rich; Philip J Rosenfeld; Carmen A Puliafito; Sander R Dubovy; Janet L Davis; Harry W Flynn; Serafin Gonzalez; William J Feuer; Richard C Lin; Geeta A Lalwani; Jackie K Nguyen; Gaurav Kumar
Journal:  Retina       Date:  2006 May-Jun       Impact factor: 4.256

5.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

6.  Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.

Authors:  Stephan Michels; Philip J Rosenfeld; Carmen A Puliafito; Erin N Marcus; Anna S Venkatraman
Journal:  Ophthalmology       Date:  2005-06       Impact factor: 12.079

7.  Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Authors:  Robert L Avery; Dante J Pieramici; Melvin D Rabena; Alessandro A Castellarin; Ma'an A Nasir; Matthew J Giust
Journal:  Ophthalmology       Date:  2006-02-03       Impact factor: 12.079

8.  Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

Authors:  Richard F Spaide; Ketan Laud; Howard F Fine; James M Klancnik; Catherine B Meyerle; Lawrence A Yannuzzi; John Sorenson; Jason Slakter; Yale L Fisher; Michael J Cooney
Journal:  Retina       Date:  2006-04       Impact factor: 4.256

9.  Age-related macular degeneration and risk for stroke.

Authors:  Tien Yin Wong; Ronald Klein; Cong Sun; Paul Mitchell; David J Couper; Hong Lai; Larry D Hubbard; A Richey Sharrett
Journal:  Ann Intern Med       Date:  2006-07-18       Impact factor: 25.391

10.  Pegaptanib for neovascular age-related macular degeneration.

Authors:  Evangelos S Gragoudas; Anthony P Adamis; Emmett T Cunningham; Matthew Feinsod; David R Guyer
Journal:  N Engl J Med       Date:  2004-12-30       Impact factor: 91.245
View more
  6 in total

1.  Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Authors:  Clement K Chan; Atul Jain; Srinivas Sadda; Neeta Varshney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

Review 2.  Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation.

Authors:  Steven Yeh; Thomas A Albini; Andrew A Moshfeghi; Robert B Nussenblatt
Journal:  Am J Ophthalmol       Date:  2012-09       Impact factor: 5.258

Review 3.  Cost effectiveness of treatments for wet age-related macular degeneration.

Authors:  Paul Mitchell; Lieven Annemans; Richard White; Meghan Gallagher; Simu Thomas
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

4.  Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.

Authors:  Lazaros Konstantinidis; Irmela Mantel; Jean-Antoine C Pournaras; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-29       Impact factor: 3.117

Review 5.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 6.  The Age-Related Eye Disease 2 Study: Micronutrients in the Treatment of Macular Degeneration.

Authors:  Aruna Gorusupudi; Kelly Nelson; Paul S Bernstein
Journal:  Adv Nutr       Date:  2017-01-17       Impact factor: 8.701
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.